Fibrosis is a common pathway in many diseases affecting organs such as the liver, kidney, and heart. The need to develop and apply non-invasive and sensitive biomarkers that can detect changes in fibrosis development as response to interventions is high. Researchers from Uppsala University including Olof Eriksson (PET Imaging Director at Antaros Medical) have authored an article looking at the targeting of collage type I by molecular imaging using positron emission tomography (PET) as a direct and quantitative way to assess fibrosis.
Read the article here: Radiolabelling and positron emission tomography imaging of a high affinity peptide binder to collagen type 1
Ex vivo autoradiograms of PET tracer binding to collagen type I in fibrotic metabolic dysfunction-associated steatohepatitis (MASH; previously called non-alcoholic steatohepatitis or NASH) vs healthy liver tissue (left) and the staining of collagen in the corresponding tissue (right) in mice